Development of CDK Inhibitors as Anticancer Agents: From Rational Design to CDK4-Specific Inhibition

Tumor Growth....................................125 6.2 Development of Nontoxic Analogs of Fascaplysin.....................................126

6.2.1 Molecular Modeling and Rationale for Chemical Syntheses .........127 6.2.2 Biological Methods ..........................................................................130